Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$59.46 USD

59.46
2,103,648

-1.21 (-1.99%)

Updated Aug 7, 2025 03:59 PM ET

After-Market: $59.10 -0.36 (-0.61%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BioMarin Gets $15M From Pfizer on Talzenna's European Nod

by Zacks Equity Research

BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.

Zacks Equity Research

Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

by Zacks Equity Research

Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

Zacks Equity Research

BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

by Zacks Equity Research

BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

Zacks Equity Research

BioMarin Announces Data on Hemophilia Candidate, Shares Fall

by Zacks Equity Research

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

Zacks Equity Research

Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion

by Zacks Equity Research

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Zacks Equity Research

BioMarin (BMRN) in Focus: Stock Moves 7.5% Higher

by Zacks Equity Research

BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

by Zacks Equity Research

Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.

Zacks Equity Research

BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research

BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.

Zacks Equity Research

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for April 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

New Strong Sell Stocks for March 29th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Zacks Equity Research

Sarepta (SRPT) Reports Positive Interim Results for DMD Drug

by Zacks Equity Research

Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.

Zacks Equity Research

New Strong Sell Stocks for March 27th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Zacks Equity Research

Why Is BioMarin (BMRN) Down 0.9% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for March 18th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

New Strong Sell Stocks for March 7th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up

by Zacks Equity Research

Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.

Zacks Equity Research

BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline

by Zacks Equity Research

BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.

Zacks Equity Research

BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

by Kinjel Shah

Here are five stocks that are attractive and most likely to be takeout targets in 2019.

Zacks Equity Research

Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

by Zacks Equity Research

Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.

Zacks Equity Research

Sarepta Stock More Than Doubles This Year So Far: Here's Why

by Zacks Equity Research

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.

Zacks Equity Research

BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.

Zacks Equity Research

Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up

by Zacks Equity Research

Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.

Zacks Equity Research

BioMarin Pharmaceutical (BMRN) Q3 Earnings Preview: What to Watch Ahead of the Release

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.